Gilead Signs a License Agreement with Xencor for its GS-9722 to Treat HIV
Gilead and Galapagos’ Report Results of Filgotinib in P-III FINCH 3 Trial for Moderate-To-Severe Active Rheumatoid Arthritis (RA)
Shots:
- Xencor to receive upfront, milestones and royalties on successful development and commercialization of product. Gilead to get exclusive license rights for GS-9722 & up to three additional anti-HIV Abs and will be responsible for research, development, regulatory and commercial activities and all costs
- Gilead will get rights to access Xencor’s Xtend extended half-life and Cytotoxic XmAb Fc platforms to develop and commercialize its GS-9722 and the agreement will further expand ability of XmAb technologies to develop therapies for HIV
- Xtend XmAb Fc is targeted to improve the immune system’s elimination of tumor and other pathologic cells by ADCC
Click here to read full press release/ article | Ref: Xencor | Image: Signbox